The addition of anti-EGFR to FOLFOX (PRIME trial) [49] or FOLFIRI (PICCOLO trial) [50] did not demonstrate a clinical benefit, with a detrimental effect of anti-EGFR therapy in BRAF-mutated CRC in the PICCOLO trial (OS: HR 1.84; 95% CI 1.10–3.08; p = 0.029). This evidence concerns the gene EGFR and colorectal carcinoma.